Format

Send to

Choose Destination
J Med Chem. 2014 Oct 9;57(19):7838-58. doi: 10.1021/jm500364u. Epub 2014 Jun 24.

Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.

Author information

1
Department of Discovery Chemistry, Merck Research Laboratories, West Point, Pennsylvania 19486, United States.

Abstract

Calcitonin gene-related peptide (CGRP) is a potent neuromodulator and vasodilator. It has been implicated in the pathogenesis of migraine by a number of lines of evidence, although its precise role has yet to be fully defined. Compelling evidence for the importance of CGRP in migraine has been provided by clinical trials with multiple small molecule CGRP receptor antagonists. These clinical studies have shown that blockade of the CGRP receptor can produce antimigraine efficacy comparable to that of the gold standard triptan class of drugs with an incidence of adverse events that appears to be relatively low. The present review describes the discovery and development of these new antimigraine agents and highlights the challenges of identifying orally acting drugs that target a family B G-protein-coupled receptor.

PMID:
24960305
DOI:
10.1021/jm500364u
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for American Chemical Society
Loading ...
Support Center